GLP-1

GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone produced by intestinal L-cells in response to food intake. It plays a central role in glucose regulation and appetite signaling, and has become the basis for one of the most extensively studied hormone systems in modern metabolic research.

What Is GLP-1?

GLP-1 is a peptide hormone derived from the proglucagon gene, released from L-cells in the small intestine and colon following nutrient intake. Its established physiological actions include:

• Glucose-dependent insulin secretion — GLP-1 stimulates insulin release from pancreatic beta cells specifically when blood glucose is elevated, a mechanism of particular research interest because it carries a lower inherent risk of hypoglycemia than some other insulin-secretion pathways.
• Glucagon suppression — GLP-1 reduces glucagon secretion from pancreatic alpha cells, contributing to its glucose-lowering effect.
• Gastric emptying delay — GLP-1 slows the rate at which the stomach empties into the small intestine, which is studied in relation to post-meal glucose control and satiety.
• Central appetite signaling — GLP-1 receptors are present in areas of the brain involved in appetite regulation, and receptor activation there is studied in relation to satiety and food intake.

Native GLP-1 is rapidly broken down in the body by the enzyme DPP-4, giving it a half-life of only a few minutes — a key reason why pharmaceutical research in this space has focused heavily on developing longer-acting GLP-1 receptor agonist molecules.

Summary of Published Research

GLP-1 biology is one of the most extensively researched areas in endocrinology, with a research base spanning basic physiology through large-scale human trials:

• Foundational endocrinology: Decades of research have characterized the incretin effect — the observation that oral glucose provokes a greater insulin response than intravenous glucose — with GLP-1 identified as a primary driver of this effect.
• Receptor and signaling research: Extensive molecular biology research has mapped the GLP-1 receptor’s signaling pathways, informing the design of longer-acting synthetic GLP-1 receptor agonists.
• Cardiometabolic research: Human clinical trials on approved GLP-1 receptor agonist medications have examined effects on body weight, glycemic control, and cardiovascular outcomes, generating one of the larger human clinical trial literatures of any hormone-based drug class in recent years.
• Ongoing mechanistic research: Active academic research continues to examine GLP-1’s roles beyond glucose and appetite regulation, including its receptor’s presence in cardiac, renal, and central nervous system tissue.

An Important Distinction

GLP-1 occupies a different regulatory position than most other compounds discussed on this site. Several synthetic GLP-1 receptor agonist medications have received FDA approval for specific, defined indications (such as type 2 diabetes and chronic weight management) when manufactured, prescribed, and dispensed as approved pharmaceutical products under a physician’s care. This content discusses GLP-1 as an endogenous hormone and general research subject — it does not refer to, endorse, or provide guidance on any specific branded or approved pharmaceutical product, nor on non-pharmaceutical research-grade GLP-1 peptides, which have not been evaluated or approved by the FDA for human use outside of approved drug channels.

Current Research Applications Being Studied

Active research areas in GLP-1 biology include:

• Incretin physiology and glucose-dependent insulin secretion mechanisms.
• Central nervous system GLP-1 receptor signaling and appetite regulation.
• Cardiovascular and renal effects of GLP-1 receptor activation.
• Combination hormone research (e.g., dual and triple receptor agonist approaches combining GLP-1 with other incretin pathways).